ApoE4 carriers with CRP levels of 3 mg/L or less had a onefold to twofold increase of risk of AD compared with ApoE3 and ApoE2 carriers with similar CRP levels (37 of 410 [9.0%] vs 58 of 1174 [4.9%] vs 8 of 245 [3.3%]; P = .003; Table 1 and Figure 1B). This evidence concerns the gene CRP and Alzheimer disease.